Your browser is no longer supported. Please, upgrade your browser.
Virpax Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.88 Insider Own58.70% Shs Outstand6.11M Perf Week-11.11%
Market Cap26.40M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float1.61M Perf Month-21.45%
Income-4.30M PEG- EPS next Q- Inst Own- Short Float0.68% Perf Quarter-
Sales- P/S- EPS this Y-31.20% Inst Trans- Short Ratio0.04 Perf Half Y-
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh0.02 P/C263.95 EPS next 5Y- ROE- 52W Range4.28 - 8.24 Perf YTD-33.84%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-47.57% Beta-
Dividend %- Quick Ratio0.00 Sales past 5Y- Gross Margin- 52W Low0.93% ATR0.48
Employees2 Current Ratio0.00 Sales Q/Q- Oper. Margin- RSI (14)39.77 Volatility5.15% 9.75%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.48 Prev Close4.50
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume274.66K Price4.32
Recom- SMA20-11.64% SMA50-17.76% SMA200-17.76% Volume131,991 Change-4.00%
Apr-05-21 12:54PM  
Mar-22-21 09:00AM  
Mar-10-21 09:00AM  
Mar-02-21 08:00AM  
Mar-01-21 11:15AM  
Feb-23-21 08:00AM  
Feb-22-21 01:52PM  
Feb-19-21 04:07PM  
Virpax Pharmaceuticals, Inc. develops and manufactures non-opioid and non-addictive based drug compounds and drug delivery systems for pain management. It offers products, such as Probudur, an injectable bupivacaine hydrogel for postoperative pain management; Epoladerm, a diclofenac metered-dose spray film for acute musculoskeletal pain; and NES100, an endogenous enkephalin intranasal spray for acute and chronic spray. The company develops drug delivery technologies, such as Topical metered-dose spray, Liposomal in Hydrogel encapsulation, and Enkephalin Intranasal spray. It also develops therapies to manage post-traumatic stress disorder (PTSD), as well as to help prevent viral spread, including influenza and SARS-CoV-2 (Covid-19). Virpax Pharmaceuticals, Inc. was founded in 2016 and is based in Malvern, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Jambulingam ThaniDirectorFeb 17Buy7.16100716100Mar 01 06:00 PM